Glow Blend (70mg)

Order Glow Blend 70mg from Eternal Peptides, a trusted peptides supplier with consistent peptide quality and rigorous third-party testing by leading labs. This premium blend combines three research peptides: GHK-Cu, BPC-157, and TB-500, a formulation designed for studies investigating tissue repair, skin health, and regenerative processes. Each batch is independently tested for purity and potency, with certificates of analysis available online. Order now for free shipping on orders above $200, with 24/7 support across the US. Sold for research use only.

What is Glow Blend?

Glow Blend is a synergistic research formulation combining three distinct peptides: GHK-Cu (glycyl-L-histidyl-L-lysine-copper complex), BPC-157 (Body Protection Compound-157), and TB-500 (Thymosin Beta-4 fragment).

The name “Glow Blend” is a colloquial label referencing research observations in dermal matrix remodeling and collagen-related pathways in preclinical models.

• GHK-Cu – a naturally occurring tripeptide first isolated from human plasma in 1973 by Dr. Loren Pickart, known for its copper-binding properties and role in tissue remodeling
• BPC-157 – a synthetic pentadecapeptide (15 amino acids) derived from a protective gastric protein sequence
• TB-500 – a synthetic analogue of the naturally occurring 43-amino acid Thymosin Beta-4 peptide, focusing on the active 17-23 fragment region

In scientific literature, this combination is primarily investigated for its potential effects on tissue repair, wound healing, collagen synthesis, and skin regeneration.

GHK-Cu has been studied extensively in vitro and in animal models for its influence on extracellular matrix remodeling and anti-inflammatory pathways. BPC-157 research focuses on accelerated healing of various tissue types, particularly tendons and ligaments, while TB-500 studies examine cellular migration and angiogenesis.

Glow Blend is supplied in lyophilized powder form to ensure optimal stability during storage and high solubility upon reconstitution, making this blend ideal for controlled research applications.

How Glow Blend Works: Mechanistic Overview

Glow Blend’s three-peptide formulation operates through complementary mechanisms targeting tissue repair and regenerative processes.

• GHK-Cu functions through copper-dependent enzymatic pathways and gene expression modulation, influencing collagen synthesis and extracellular matrix remodeling
• BPC-157 appears to interact with growth factor receptors and signaling cascades involved in angiogenesis and cytoprotective responses
• TB-500 promotes cellular migration through actin regulation and upregulation of proteins involved in wound healing

Together, these peptides have demonstrated effects on inflammation modulation, vascular formation, and tissue regeneration in preclinical models. Animal studies have observed accelerated wound closure, improved tendon healing, and enhanced dermal thickness following administration of these individual peptides.

However, the combined formulation represents a novel research approach.

Collagen Synthesis and Extracellular Matrix Remodeling

GHK-Cu stimulates fibroblast proliferation and increases production of structural proteins including collagen types I and III, elastin, and glycosaminoglycans[1]. The copper component acts as a cofactor for lysyl oxidase, an enzyme critical for collagen and elastin cross-linking. 

In vitro studies demonstrate that GHK-Cu upregulates genes associated with tissue repair while simultaneously suppressing inflammatory and fibrotic markers[2]. Rodent models of dermal injury have shown significantly increased wound tensile strength and organized collagen deposition in GHK-Cu-treated groups compared to controls[3].

The peptide also appears to influence transforming growth factor-beta (TGF-β) signaling, potentially reducing excessive scar formation while promoting functional tissue restoration.

Angiogenesis and Vascular Development

Both BPC-157 and TB-500 have demonstrated pro-angiogenic properties in preclinical research. TB-500 upregulates vascular endothelial growth factor (VEGF) expression and promotes endothelial cell migration through actin polymerization pathways. This peptide facilitates the formation of new capillary networks, essential for delivering oxygen and nutrients to regenerating tissues[4]. 

BPC-157 appears to influence the nitric oxide (NO) pathway and VEGF receptor activation, contributing to blood vessel formation and stabilization. Animal studies examining tendon injuries, muscle damage, and ischemic conditions have documented enhanced vascular density in treated subjects.

The increased perfusion observed in these models correlates with accelerated healing timelines and improved functional recovery in tissue repair assessments.

Cytoprotection and Anti-Inflammatory Responses

BPC-157 exhibits notable cytoprotective effects across multiple tissue types in animal research. The peptide appears to stabilize cellular membranes, reduce oxidative stress, and modulate inflammatory cytokine production including tumor necrosis factor-alpha (TNF-α) and interleukin-6 (IL-6)[5].

Studies in rodent models of gastrointestinal injury, tendon damage, and ligament tears have shown reduced inflammatory markers and preserved tissue architecture following BPC-157 administration[6].

GHK-Cu similarly demonstrates anti-inflammatory properties by suppressing NF-κB signaling and reducing expression of pro-inflammatory mediators[7]. The combined formulation may provide synergistic protective effects, though this specific combination requires further investigation.

These mechanisms support tissue preservation during injury and may facilitate more favorable healing environments in experimental models.

Cellular Migration and Wound Closure

TB-500’s primary mechanism involves regulation of actin, a structural protein essential for cell movement and shape. By binding to G-actin, TB-500 promotes actin polymerization and cytoskeletal reorganization, enabling enhanced cellular migration toward injury sites[8]. 

This mechanism is particularly relevant for keratinocyte and fibroblast migration during wound healing. In vitro scratch assays demonstrate accelerated gap closure in TB-500-treated cell cultures, while animal models of dermal wounds show faster epithelialization and reduced healing times in treated groups[9].

The peptide also appears to reduce apoptosis in damaged tissues and may influence stem cell differentiation pathways. These cellular effects translate to observable improvements in wound contraction, re-epithelialization rates, and overall tissue integrity in preclinical wound healing studies.

Note: While individual components of Glow Blend have been studied extensively in cellular assays and animal models, controlled human clinical trials remain limited. This blend has not been systematically evaluated in clinical settings, and all findings should be interpreted within a preclinical research context. Any observed effects in animal models cannot be directly extrapolated to human outcomes.

Glow Blend Research Value (Applications)

Glow Blend’s combined peptide formulation has been investigated across several research domains, primarily focusing on tissue regeneration, dermal aging models, musculoskeletal repair, and wound healing.

The observations summarized below are derived exclusively from preclinical studies, including cellular assays, rodent models, and other animal research. These findings do not imply any human therapeutic benefits, as controlled clinical evidence is absent.

Glow Blend is not approved for medical, veterinary, or clinical use, and Eternal Peptides does not promote or advocate for any such applications.

Dermal Aging and Skin Regeneration Studies

Animal models examining photoaged and chronologically aged skin have shown measurable improvements in dermal thickness, collagen density, and elasticity following treatment with GHK-Cu and related peptides.

Rodent studies demonstrate increased expression of collagen I and III genes, enhanced fibroblast activity, and improved extracellular matrix organization[1]. Histological analyses reveal reduced matrix metalloproteinase (MMP) activity, enzymes responsible for collagen degradation, alongside increased tissue inhibitors of metalloproteinases (TIMPs).

In the studies, UV-damaged skin models treated with copper peptides exhibited decreased oxidative stress markers and improved structural protein arrangement compared to untreated controls[10].

Wound Healing and Tissue Repair Models

Preclinical wound healing studies consistently demonstrate accelerated closure rates and improved tissue quality in animals treated with BPC-157 and TB-500[11]. Rodent models of full-thickness dermal wounds show enhanced re-epithelialization, increased granulation tissue formation, and superior tensile strength at healing sites.

Studies examining surgical incisions report reduced healing times and improved scar cosmesis in treated groups. The combination appears particularly effective in models of impaired healing, such as diabetic rodent wounds, where vascular compromise typically delays recovery. 

In similar studies, microscopic examination revealed enhanced angiogenesis, organized collagen deposition, and reduced inflammatory cell infiltration in treated wounds[12].

Musculoskeletal and Connective Tissue Research

BPC-157 and TB-500 have been extensively studied in animal models of tendon, ligament, and muscle injuries. Rodent Achilles tendon transection models demonstrate accelerated healing, improved biomechanical properties, and enhanced collagen fiber alignment in treated groups[7]. 

Muscle crush injury studies show reduced necrosis, faster regeneration of muscle fibers, and improved functional recovery[1]. Similarly, ligament injury models reveal increased cellular proliferation at injury sites and superior structural organization during the healing phase. In these preclinical models, GLOW blend constituent peptides appear to influence satellite cell activation and migration, which are critical processes in muscle tissue regeneration.

Inflammation and Oxidative Stress Models

GHK-Cu demonstrates potent antioxidant properties in cellular and animal studies, reducing reactive oxygen species (ROS) and lipid peroxidation markers.

Research models of inflammatory conditions show decreased pro-inflammatory cytokine expression and reduced NF-κB pathway activation following peptide treatment. BPC-157 exhibits protective effects in gastric ulcer models, ischemia-reperfusion injury studies, and inflammatory bowel disease research in rodents, consistently showing tissue preservation and reduced inflammatory damage.

Laboratory studies show these peptides reduce cellular damage from inflammation and oxidative stress, protecting tissues in various injury and disease models..

Peptide Characteristics: Glow Blend

Note: This formulation combines three distinct peptides in a single preparation. Individual component characteristics may vary by batch; consult product-specific documentation for precise composition details.

Handling & Storage Guidelines — Glow Blend

Store unopened vials at -4°F to -22°F (-20°C to -30°C) in a freezer, protected from light and moisture. Under these conditions, lyophilized Glow Blend maintains stability for up to 24 months. Avoid repeated temperature fluctuations and ensure vials remain sealed until ready for reconstitution.

Reconstitute lyophilized powder using bacteriostatic water or sterile saline. Add solvent slowly along the vial wall to minimize foaming and peptide degradation. Gently swirl (do not shake vigorously) until powder is fully dissolved. Allow the solution to rest for 1-2 minutes before use.

For the best stability, purity, and consistent results, get bacteriostatic water with your Glow Blend order.

Once reconstituted, store solutions at 36°F to 46°F (2°C to 8°C) in a refrigerator for short-term use (up to 30 days). For extended storage, aliquot the reconstituted solution into sterile vials and store at -4°F to -22°F (-20°C to -30°C). Aliquoting prevents repeated freeze-thaw cycles, which can degrade peptide integrity.

Handle all peptides using aseptic technique in appropriate laboratory settings. Wear personal protective equipment (PPE) including gloves and lab coats. Ensure handling procedures comply with institutional biosafety guidelines and research protocols and dispose of materials according to local regulations for laboratory waste.

COA / Quality Assurance 

Eternal Peptides provides comprehensive Certificates of Analysis (COAs) for every lot of Glow Blend, ensuring transparency, traceability, and research-grade quality. Each COA is generated through independent third-party testing by leading analytical laboratories, including Janoshik, recognized for rigorous peptide verification standards.

All test results are accessible on our lab tests page.

CoAs typically document:

• Peptide Identity Confirmation: High-Performance Liquid Chromatography (HPLC) and mass spectrometry analysis verify the molecular structure and composition of each peptide component (GHK-Cu, BPC-157, TB-500).
• Purity Assessment: Quantitative purity analysis, typically demonstrating ≥99% purity for each individual peptide in the formulation.
• Sterility Testing: Microbiological testing confirms absence of bacterial and fungal contamination in lyophilized preparations.
• Endotoxin Levels: Limulus Amebocyte Lysate (LAL) assay results ensure endotoxin levels meet acceptable thresholds for research applications (<1.0 EU/mg).
• Storage and Handling Recommendations: Lot-specific guidance for optimal storage conditions and reconstitution protocols.

By partnering with independent, accredited laboratories (such as Janoshik and Finnrick Analytics), Eternal Peptides ensures unbiased quality verification.

Legal / Regulatory Disclaimer — Glow Blend

Glow Blend is provided strictly for laboratory research purposes only. This product is not approved by the U.S. Food and Drug Administration (FDA) or any regulatory authority for human use, veterinary use, clinical administration, therapeutic applications, or diagnostic procedures. Safety and efficacy in humans have not been established through controlled clinical trials.

Purchasers are solely responsible for ensuring compliance with all applicable federal, state, and local regulations, as well as institutional biosafety policies and research-use guidelines. 

By purchasing this product, you acknowledge that it is intended exclusively for in vitro research, preclinical studies, and other lawful scientific investigations conducted by qualified researchers in appropriate laboratory settings.

Scientific References

1. Pickart L, Margolina A. Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data. Int J Mol Sci. 2018 Jul 7;19(7):1987.

https://pmc.ncbi.nlm.nih.gov/articles/PMC6073405/ 

2. Pickart L, Vasquez-Soltero JM, Margolina A. GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration. Biomed Res Int. 2015;2015:648108.

https://pmc.ncbi.nlm.nih.gov/articles/PMC4508379/ 

3. Vadivel Arul, Reena Kartha, Rajadas Jayakumar, A therapeutic approach for diabetic wound healing using biotinylated GHK incorporated collagen matrices,

Life Sciences, Volume 80, Issue 4, 2007, Pages 275-284, ISSN 0024-3205.

https://www.sciencedirect.com/science/article/abs/pii/S0024320506007211 

4. Maar K, Hetenyi R, Maar S, Faskerti G, Hanna D, Lippai B, Takatsy A, Bock-Marquette I. Utilizing Developmentally Essential Secreted Peptides Such as Thymosin Beta-4 to Remind the Adult Organs of Their Embryonic State-New Directions in Anti-Aging Regenerative Therapies. Cells. 2021 May 28;10(6):1343.

https://pmc.ncbi.nlm.nih.gov/articles/PMC8228050/ 

5. Sikiric P, Skrtic A, Gojkovic S, Krezic I, Zizek H, Lovric E, Sikiric S, Knezevic M, Strbe S, Milavic M, Kokot A, Blagaic AB, Seiwerth S. Cytoprotective gastric pentadecapeptide BPC 157 resolves major vessel occlusion disturbances, ischemia-reperfusion injury following Pringle maneuver, and Budd-Chiari syndrome. World J Gastroenterol. 2022 Jan 7;28(1):23-46.

https://pmc.ncbi.nlm.nih.gov/articles/PMC8793015/ 

6. Vasireddi N, Hahamyan H, Salata MJ, Karns M, Calcei JG, Voos JE, Apostolakos JM. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS J. 2025 Jul 31:15563316251355551.

https://pmc.ncbi.nlm.nih.gov/articles/PMC12313605/ 

7. Mao S, Huang J, Li J, Sun F, Zhang Q, Cheng Q, Zeng W, Lei D, Wang S, Yao J. Exploring the beneficial effects of GHK-Cu on an experimental model of colitis and the underlying mechanisms. Front Pharmacol. 2025 Jul 2;16:1551843.

https://pmc.ncbi.nlm.nih.gov/articles/PMC12263609/ 

8. Bai Y, Zhao F, Wu T, Chen F, Pang X. Actin polymerization and depolymerization in developing vertebrates. Front Physiol. 2023 Sep 8;14:1213668.

https://pmc.ncbi.nlm.nih.gov/articles/PMC10515290/ 

9. Liao HJ, Chen HT, Chang CH. Peptides for Targeting Chondrogenic Induction and Cartilage Regeneration in Osteoarthritis. Cartilage. 2024 Sep 18:19476035241276406.

https://pmc.ncbi.nlm.nih.gov/articles/PMC11556548/ 

10. Borkow G. Using Copper to Improve the Well-Being of the Skin. Curr Chem Biol. 2014 Aug;8(2):89-102.

https://pmc.ncbi.nlm.nih.gov/articles/PMC4556990/ 

11. Cushman CJ, Ibrahim AF, Smith AD, Hernandez EJ, MacKay B, Zumwalt M. Local and Systemic Peptide Therapies for Soft Tissue Regeneration: A Narrative Review. Yale J Biol Med. 2024 Sep 30;97(3):399-413.

https://pmc.ncbi.nlm.nih.gov/articles/PMC11426299/ 

12. Peter Holmberg Jørgensen, Troels Torp Andreassen, Karin Damm Jørgensen, Growth hormone influences collagen deposition and mechanical strength of intact rat skin. A dose-response study, Acta Endocrinologica, Volume 120, Issue 6, Jun 1989, Pages 767–772.

https://academic.oup.com/ejendo/article-abstract/120/6/767/6773641?redirectedFrom=fulltext